Anlon Healthcare Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company has a good return on equity (ROE) track record: 3 Years ROE 42.5%
- Company has a healthy return on capital (ROCE) of 20.9%
- Latest quarter profit grew 1251.3% YoY, showing strong momentum
- Operating margins have improved to 26.1% from 11.1%
- Company comfortably covers its interest (10.3x coverage)
- Attractively priced for its growth - PEG of 0.4
CONS
- Operating cash flow has been negative in recent years
- Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT -1.24x)
- Free cash flow has been persistently negative
- Though reporting repeated profits, the company pays out little dividend (0.0%)
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1899.00 | 37.67 | 455633.71 | 0.84 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9100.00 | 82.59 | 241576.41 | 0.33 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4850.00 | 84.58 | 184478.41 | 0.78 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| CIPLA | 1385.00 | 33.19 | 111888.39 | 0.94 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| ZYDUSLIFE | 1121.00 | 24.78 | 111820.18 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| LAURUSLABS | 1840.00 | 90.93 | 99417.45 | 0.11 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| LUPIN | 2111.00 | 17.46 | 96528.82 | 0.85 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| DRREDDY | 1154.00 | 29.89 | 96322.06 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| MANKIND | 2328.55 | 47.09 | 96179.61 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| AUROPHARMA | 1653.30 | 25.62 | 95127.23 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| GLENMARK | 2427.00 | 38.10 | 68495.93 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| AHCL | 15.68 | 29.23 | 833.42 | 0.00 | 82.81 | — | 875.63 | 1689.56 | 21.98 | 17.81 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| 38 | 24 | 9 | 49 | 33 | 52 | 36 | 55 | 310 | |
| 31 | 17 | 9 | 32 | 27 | 38 | 23 | 42 | 251 | |
| Operating Profit | 7 | 8 | 1 | 17 | 6 | 14 | 12 | 14 | 58 |
| OPM % | 18.29% | 31.11% | 6.20% | 35.13% | 18.74% | 26.32% | 34.68% | 25.10% | 18.87% |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 10 |
| Depreciation | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 7 |
| Profit before Tax | 6 | 6 | -0 | 15 | 5 | 12 | 11 | 13 | 59 |
| Tax % | 31.83% | 57.86% | -758.62% | -7.49% | 29.20% | 25.14% | 51.41% | 22.36% | 18.75% |
| Net Profit | 4 | 3 | -2 | 17 | 4 | 9 | 5 | 10 | 48 |
| 0.41 | 0.41 | -0.83 | 5.15 | 2.22 | 2.22 | 1.13 | 2.15 | 0.09 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|
| 57 | 113 | 67 | 120 | 176 | 453 | |
| 52 | 100 | 51 | 88 | 130 | 355 | |
| Operating Profit | 6 | 13 | 16 | 33 | 46 | 98 |
| OPM % | 9.72% | 11.11% | 23.59% | 27.06% | 26.14% | 21.73% |
| 0 | 0 | 0 | 0 | 0 | 1 | |
| Interest | 4 | 4 | 4 | 4 | 4 | 13 |
| Depreciation | 2 | 2 | 2 | 2 | 1 | 8 |
| Profit before Tax | -0 | 7 | 10 | 27 | 41 | 95 |
| Tax % | -0.00% | 16.78% | 0.96% | 23.69% | 31.63% | 23.74% |
| Net Profit | -0 | 6 | 10 | 21 | 28 | 72 |
| EPS | -0.09 | 4.85 | 6.04 | 5.15 | 5.23 | — |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 16%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 68%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- 72%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- 50%
- 3 Years:
- 43%
- Last Year:
- 19%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 12 | 12 | 16 | 40 | 53 |
| -10 | -5 | 5 | 41 | 157 | |
| 60 | 66 | 75 | 58 | 46 | |
| Trade Payables | 15 | 25 | 20 | 20 | 39 |
| 8 | 12 | 12 | 23 | 22 | |
| Total Liabilities | 85 | 112 | 128 | 181 | 317 |
| 27 | 26 | 27 | 23 | 40 | |
| 2 | 4 | 1 | 1 | 10 | |
| 27 | 27 | 42 | 50 | 76 | |
| 0 | 0 | 39 | 75 | 104 | |
| Cash & Bank | 2 | 1 | 2 | 1 | 3 |
| 28 | 54 | 17 | 31 | 83 | |
| Total Assets | 85 | 112 | 128 | 181 | 317 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| -2 | -3 | -3 | -23 | -46 | |
| Cash from Investing | -0 | -0 | -3 | 3 | -28 |
| Cash from Financing | 3 | 2 | 8 | 19 | 76 |
| 1 | -1 | 2 | -1 | 2 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| PER SHARE | |||||
| EPS (₹) | -0.09 | 4.85 | 6.04 | 5.15 | 5.23 |
| Book Value (₹) | 1.30 | 6.15 | 13.14 | 20.18 | 39.47 |
| Dividend per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash EPS (₹) | 0.14 | 0.64 | 0.72 | 0.56 | 0.55 |
| PROFITABILITY | |||||
| Operating Margin % | 10.41% | 11.11% | 23.59% | 27.06% | 26.14% |
| Net Margin % | -0.19% | 5.16% | 14.50% | 17.06% | 15.76% |
| ROE % | -6.93% | 130.37% | 67.99% | 40.45% | 19.17% |
| ROCE % | 6.42% | 15.42% | 15.48% | 24.83% | 22.38% |
| -0.13% | 5.92% | 8.06% | 13.27% | 11.16% | |
| EFFICIENCY | |||||
| Debtor Days | 130 | 104 | 226 | 173 | 185 |
| Inventory Days | 170 | 87 | 188 | 140 | 130 |
| Payable Days | 128 | 84 | 246 | 97 | 96 |
| 172 | 106 | 169 | 215 | 220 | |
| FINANCIAL HEALTH | |||||
| Debt to Equity (x) | 40.14x | 9.54x | 3.86x | 0.83x | 0.22x |
| Interest Coverage (x) | 0.97x | 2.78x | 3.33x | 7.63x | 10.34x |
| 2.00x | 1.97x | 2.01x | 2.64x | 2.57x | |
| GROWTH | |||||
| Revenue Growth % | 0.00% | 97.54% | -41.01% | 80.65% | 46.73% |
| Operating Profit Growth % | 0.00% | 114.98% | 23.69% | 106.87% | 41.79% |
| Net Profit Growth % | 0.00% | 5503.90% | 65.93% | 112.47% | 35.53% |
| 0.00% | 5503.90% | 24.45% | -14.70% | 1.62% | |
| VALUATION | |||||
| P/E (x) | 0.00x | 0.00x | 0.00x | 0.00x | 2.13x |
| P/B (x) | 0.00x | 0.00x | 0.00x | 0.00x | 2.82x |
| Dividend Yield % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 0.00x | 6.39x | 6.00x | 3.21x | 13.66x |
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-05 - Anlon Healthcare Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 05, 2026. Further, the company has informed the Exchange regarding voting results.
2026-09-05 - Anlon Healthcare Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 05, 2026
2026-08-25 - Anlon Healthcare Limited has informed the Exchange regarding Corrigendum to Notice of Annual General Meeting to be held on September 05, 2026
2026-08-17 - Anlon Healthcare Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-14 - Anlon Healthcare Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 05, 2026
2026-08-14 - Submission of Monitoring Agency Report for the quarter ended June 30, 2026.
2026-08-13 - Anlon Healthcare Limited has informed the Exchange that Record date for the purpose of Annual General Meeting is 28-Aug-2026.
2026-08-13 - Anlon Healthcare Limited has informed the Exchange regarding Outcome of Board Meeting held on August 13, 2026.
2026-08-13 - Anlon Healthcare Limited has informed the Exchange about Others
News
Recent coverage and analyst commentary for AHCL
Loading news…
AI Stock Analyst
Anlon Healthcare Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account